MA43231B1 - Bloqueur des canaux sodiques - Google Patents
Bloqueur des canaux sodiquesInfo
- Publication number
- MA43231B1 MA43231B1 MA43231A MA43231A MA43231B1 MA 43231 B1 MA43231 B1 MA 43231B1 MA 43231 A MA43231 A MA 43231A MA 43231 A MA43231 A MA 43231A MA 43231 B1 MA43231 B1 MA 43231B1
- Authority
- MA
- Morocco
- Prior art keywords
- sodium channel
- channel blocker
- present
- prevention
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La présente invention concerne un composé représenté par la formule chimique, ou un sel pharmaceutiquement acceptable de celui-ci. Le composé selon la présente invention peut être utilement utilisé pour la prévention ou le traitement de maladies liées aux bloqueurs des canaux sodiques.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150159637 | 2015-11-13 | ||
| PCT/KR2016/013029 WO2017082688A1 (fr) | 2015-11-13 | 2016-11-11 | Bloqueur des canaux sodiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43231B1 true MA43231B1 (fr) | 2020-08-31 |
Family
ID=58695815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43231A MA43231B1 (fr) | 2015-11-13 | 2016-11-11 | Bloqueur des canaux sodiques |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US10227338B2 (fr) |
| EP (1) | EP3375782B1 (fr) |
| JP (1) | JP6559894B2 (fr) |
| KR (1) | KR102245930B1 (fr) |
| CN (1) | CN108349963B (fr) |
| AU (1) | AU2016351526B2 (fr) |
| BR (1) | BR112018009754B1 (fr) |
| CA (1) | CA3003119C (fr) |
| CL (1) | CL2018001281A1 (fr) |
| CO (1) | CO2018005064A2 (fr) |
| EC (1) | ECSP18038014A (fr) |
| ES (1) | ES2821962T3 (fr) |
| HK (1) | HK1251229A1 (fr) |
| HR (1) | HRP20201695T1 (fr) |
| HU (1) | HUE052569T2 (fr) |
| MA (1) | MA43231B1 (fr) |
| MX (1) | MX2018005940A (fr) |
| MY (1) | MY194015A (fr) |
| NZ (1) | NZ742069A (fr) |
| PE (1) | PE20181301A1 (fr) |
| PH (1) | PH12018500999A1 (fr) |
| PL (1) | PL3375782T3 (fr) |
| PT (1) | PT3375782T (fr) |
| RS (1) | RS60927B1 (fr) |
| RU (1) | RU2705578C1 (fr) |
| SA (1) | SA518391540B1 (fr) |
| SG (1) | SG11201803867TA (fr) |
| SI (1) | SI3375782T1 (fr) |
| TN (1) | TN2018000157A1 (fr) |
| WO (1) | WO2017082688A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2019114964A (ru) * | 2016-10-17 | 2020-11-17 | Дженентек, Инк. | Терапевтические средства и способы их применения |
| WO2020052509A1 (fr) * | 2018-09-10 | 2020-03-19 | 成都康弘药业集团股份有限公司 | Composé sulfonamide servant de bloqueur de canaux sodiques et ses utilisations |
| CN112759559B (zh) * | 2019-11-06 | 2022-08-12 | 成都康弘药业集团股份有限公司 | 作为钠通道阻滞剂的磺酰胺类化合物及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5591761A (en) * | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5464853A (en) * | 1993-05-20 | 1995-11-07 | Immunopharmaceutics, Inc. | N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
| PT1612208E (pt) * | 2001-03-12 | 2011-10-12 | Ono Pharmaceutical Co | Composto de n-fenilarilsulfonamida, composição farmacêutica compreendendo o composto como ingrediente activo, intermediários de síntese para o composto e processos para a sua preparação |
| JP2006290791A (ja) * | 2005-04-11 | 2006-10-26 | Astellas Pharma Inc | アゾール置換スルホニルベンゼン誘導体 |
| US20090221581A1 (en) * | 2005-05-25 | 2009-09-03 | Philipp Wabnitz | Methods of treating pain |
| US7888345B2 (en) | 2006-06-09 | 2011-02-15 | Merck Sharp & Dohme Corp. | Benzaepinones as sodium channel blockers |
| CA2695613A1 (fr) * | 2006-12-19 | 2008-06-26 | Pharmos Corporation | Derives sulfonamides avec indications therapeutiques |
| SA08290245B1 (ar) | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
| JP2008290791A (ja) * | 2007-05-22 | 2008-12-04 | Funai Electric Co Ltd | 画像形成装置 |
| US8124610B2 (en) * | 2007-07-13 | 2012-02-28 | Icagen Inc. | Sodium channel inhibitors |
| PT2385938E (pt) * | 2009-01-12 | 2015-06-02 | Pfizer Ltd | Derivados de sulfonamida |
| EP2593432B1 (fr) | 2010-07-12 | 2014-10-22 | Pfizer Limited | Dérivés de n-sulfonylbenzamide utiles comme inhibiteurs du canal sodique voltage-dépendant |
| US9481677B2 (en) | 2011-10-31 | 2016-11-01 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
| EP2788332A1 (fr) | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Inhibiteurs aryle et hétéroaryle bicycliques des canaux calciques |
| CA2857603C (fr) | 2011-12-15 | 2016-08-02 | Pfizer Limited | Derives de sulfonamide |
| WO2013093688A1 (fr) | 2011-12-19 | 2013-06-27 | Pfizer Limited | Dérivés sulfonamides et leur utilisation en tant qu'inhibiteurs de vgsc |
| WO2013177224A1 (fr) | 2012-05-22 | 2013-11-28 | Genentech, Inc. | Benzamides n-substitués et leur utilisation dans le traitement de la douleur |
| US9376429B2 (en) * | 2012-10-15 | 2016-06-28 | Daewoong Pharmaceutical Co., Ltd. | Sodium channel blockers, preparation method thereof and use thereof |
| US20170145003A1 (en) * | 2014-02-27 | 2017-05-25 | Mark G. DeGiacomo | Heterocyclic inhibitors of the sodium channel |
-
2016
- 2016-11-11 CA CA3003119A patent/CA3003119C/fr active Active
- 2016-11-11 ES ES16864614T patent/ES2821962T3/es active Active
- 2016-11-11 RU RU2018119954A patent/RU2705578C1/ru active
- 2016-11-11 PL PL16864614.9T patent/PL3375782T3/pl unknown
- 2016-11-11 PT PT168646149T patent/PT3375782T/pt unknown
- 2016-11-11 CN CN201680066269.7A patent/CN108349963B/zh active Active
- 2016-11-11 MY MYPI2018000662A patent/MY194015A/en unknown
- 2016-11-11 JP JP2018524451A patent/JP6559894B2/ja active Active
- 2016-11-11 SI SI201630902T patent/SI3375782T1/sl unknown
- 2016-11-11 PE PE2018000765A patent/PE20181301A1/es unknown
- 2016-11-11 US US15/771,775 patent/US10227338B2/en active Active
- 2016-11-11 WO PCT/KR2016/013029 patent/WO2017082688A1/fr active Application Filing
- 2016-11-11 HU HUE16864614A patent/HUE052569T2/hu unknown
- 2016-11-11 KR KR1020160150511A patent/KR102245930B1/ko active IP Right Grant
- 2016-11-11 SG SG11201803867TA patent/SG11201803867TA/en unknown
- 2016-11-11 MA MA43231A patent/MA43231B1/fr unknown
- 2016-11-11 NZ NZ742069A patent/NZ742069A/en unknown
- 2016-11-11 BR BR112018009754-3A patent/BR112018009754B1/pt active IP Right Grant
- 2016-11-11 RS RS20201235A patent/RS60927B1/sr unknown
- 2016-11-11 EP EP16864614.9A patent/EP3375782B1/fr active Active
- 2016-11-11 TN TNP/2018/000157A patent/TN2018000157A1/en unknown
- 2016-11-11 AU AU2016351526A patent/AU2016351526B2/en active Active
- 2016-11-11 MX MX2018005940A patent/MX2018005940A/es active IP Right Grant
-
2018
- 2018-05-08 PH PH12018500999A patent/PH12018500999A1/en unknown
- 2018-05-09 SA SA518391540A patent/SA518391540B1/ar unknown
- 2018-05-10 CL CL2018001281A patent/CL2018001281A1/es unknown
- 2018-05-11 CO CONC2018/0005064A patent/CO2018005064A2/es unknown
- 2018-05-18 EC ECIEPI201838014A patent/ECSP18038014A/es unknown
- 2018-08-17 HK HK18110615.4A patent/HK1251229A1/zh unknown
-
2020
- 2020-10-20 HR HRP20201695TT patent/HRP20201695T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| MA51431B1 (fr) | Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase | |
| SA518400547B1 (ar) | مشتقات بيرازولو بيريميدين كمثبط كيناز | |
| MA46337B1 (fr) | Composé de pyridine | |
| MY196186A (en) | Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor | |
| ECSP20075270A (es) | Compuestos | |
| TN2020000081A1 (en) | Amino-methyl piperidine derivative as kinase inhibitor | |
| MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| MY197698A (en) | Oxysterols and methods of use thereof | |
| EA201892430A1 (ru) | Синтез индазолов | |
| MA40895A (fr) | Synthèse de copanlisib et son sel de dichlorhydrate | |
| MA40302B1 (fr) | Dérivés de carbazole | |
| UA122882C2 (uk) | Синтез індазолів | |
| MA43231B1 (fr) | Bloqueur des canaux sodiques | |
| MX2019002369A (es) | Compuestos para el tratamiento de enfermedades asociadas con una disfuncion mitocondrial. | |
| MA46039B1 (fr) | Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain | |
| PH12019502046A1 (en) | Pyrrolotriazine derivatives as kinase inhibitor | |
| MA42602B1 (fr) | Antagonistes du recepteur cgrp |